dkNET community events and announcements in September, 2023

05:21pm September 7, 2023
Ko-Wei Lin

News Funding Opportunity Event

Dear dkNET Community,

dkNET provides updates on activities of interest to the NIDDK-supported community. You could keep up to date on these activities through our Twitter feed @dkNET_info, through our Community Calendar, or through dkNET e-mail list. If you have an event or funding opportunities you'd like to advertise, please contact us info_at_dknet.org.

dkNET News

dkNET Office Hours for Data Management and Sharing Mandate: Are you ready for the new NIH Data Management and Sharing Plan (effective Jan. 25, 2023)? Have questions or need help? Join dkNET Office Hours on Friday, September 22, 2023, 11 am - 12 pm PT! Link: https://dknet.org/about/blog/265

dkNET Summer Program: The 2023 dkNET Summer of Data Student Program recently concluded (June 12 - July 21, 2023). This year we selected 15 students (high school, undergraduate, and graduate) from 12 different institutions. Congratulations to these awardees who presented stellar final presentations and completed the program! We wish you all successful careers in research! https://dknet.org/about/summer_program_student_2023

Join NIDDK Central Repository 20th Anniversary Virtual Workshop on September 19-20, 2023: dkNET Co-PI Dr. Jeffrey Grethe will be the panelist of the session VI:Supporting NIDDK-Funded Research and Expanding NIDDK’s Data Ecosystem at the NIDDK Central Repository 20th Anniversary Workshop: Promoting Secondary Research to Accelerate Medical Breakthroughs and Innovation. Join us to learn more about NIDDK's data ecosystem! More information: https://dknet.org/about/dknetnews/2647

New Blog Article Published by dkNET Summer Student We're excited to share an article published by CCRA blog and written by Theodore Nelson, one of our participants in the 2023 dkNET Summer of Data Student Program. Discover his perspective on the program and what he's learned about FAIR data! More information: https://dknet.org/about/blog/2660

Events in September 2023

Sep. 06, 2023

Abstract Submission Deadline: 3rd Annual PKD RRC Annual Symposium

The PKD RRC is composed of a central coordinating site (University of Maryland, Baltimore); three research and translation core centers (The University of Alabama at Birmingham; Kansas University Medical Center; University of Maryland, Baltimore); and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

Meeting Objectives

Identify state-of-the-art techniques that could be applied to advance our understanding of PKD biology.
Discuss challenges and gaps in PKD research that, if addressed, could move the field forward.
Promote broad awareness of advances in PKD research and highlight existing PKD research resources.
Foster interaction among members of the scientific community, including PKD researchers, early-stage investigators, and researchers who are new to the PKD field.
Obtain feedback from the research community, with respect to what tools and resources are necessary to advance PKD research.

Abstract submission deadline: September 6, 2023
Meeting dates: September 26-27, 2023.
More information: https://www.scgcorp.com/PKDRRC2023/Default

Sep. 08, 2023

NIH Obesity Research Task Force Symposium: Medications to Treat Obesity: Past, Present, and Future

This symposium explores the history of medications to treat obesity, the mechanisms of action of anti-obesity medications, pivotal studies of newer medications in adults and children, use of anti-obesity medications in clinical practice, and issues related to access to obesity treatment and health equity.

Location: Bethesda, MD, USA

More information: https://www.niddk.nih.gov/news/meetings-workshops/2023/nih-ortf-symp osium-medications-to-treat-obesity

Sep. 15, 2023

NIDDK 2023 Annual Mid-Atlantic Diabetes and Obesity Research Symposium

The goal of this meeting is to encourage scientific exchanges, interactions, and collaborations at the regional level. The 2023 Annual Mid-Atlantic Diabetes and Obesity Research Symposium is co-organized by the Diabetes, Endocrinology, and Obesity Branch (DEOB) at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH); the Perelman School of Medicine at the University of Pennsylvania; University of Maryland School of Medicine and The Johns Hopkins University, School of Medicine. Meeting Date: September 22, 2023. More information: https://www.niddk.nih.gov/news/meetings-workshops/2023/annual-mid-atlantic-diabetes-and-obesity-research-symposium?utm_medium=e-mail&utm_source=Meetings%20%26%20Workshops

Sep. 19-20, 2023

NIDDK Central Repository 20th Anniversary Seminar & Workshop: Promo ting Secondary Research to Accelerate Medical Breakthroughs and Innovation

The workshop sessions are to highlight secondary use research that utilized resources generated from NIDDK-funded clinical research projects, review NIDDK’s Data Ecosystem past, present and future, and launch a data challenge platform as part of the program’s vision for the future.

More information: https://www.niddk.nih.gov/news/meetings-workshops/2023/central-repository-20th-anniversary-seminar-and-workshop?utm_medium=e-mail&utm_source=Meetings%20%26%20Workshops

Sep. 21, 2023

UK Reproducibility Network Webinar: Antibodies and research reprodu cibility

Antibodies are one of the most important tools used in biomedical and fundamental biology research. They are known to be an important driver of irreproducibility in research, with issues around the quality of the reagents, the validation of the reagents for the specific purpose, variation in batches and the transparency of reporting of both methods and results. Although the problem may appear to be simple at first sight, the problem has persisted for more than a decade since it was first highlighted. This has led to some blaming manufacturers, and others blaming “lax” researchers. Like many other reproducibility problems in research, it is likely driven by several complex factors, and an effective solution likely involves changes to the research environment and culture. The Only Good Antibodies (OGA) community was set up to try to address this problem. It is a diverse cross disciplinary collaboration of individuals and partner organisations with interests in biomedical research, behavioural science, meta science, data science and research assessment. This seminar will introduce the problem, primarily with a focus on understanding different models of addressing similar problems throughout research.

More information: https://www.ukrn.org/event/antibodies-sep23/

Sep. 22, 2023

NIDDK 2023 Annual Mid-Atlantic Diabetes and Obesity Research Symposium

Location: Bethesda, MD, USA

More information: https://www.niddk.nih.gov/news/meetings-workshops/2023/annual-mid-atlantic-diabetes-and-obesity-research-symposium?utm_medium=e-mail&\;utm_source=Meetings%20%26%20Workshops

Sep. 22, 2023

dkNET Office Hours - "Are You Ready For 2023: New NIH Data Management And Sharing Mandates"

For all proposals submitted on/after January 25 2023, NIH will require the sharing of data from all NIH funded studies. Do you have appropriate data management practices and sharing plans in place to meet these requirements? Have questions or need some help? Join the dkNET office hours to learn about NIH’s policy (NOT-OD-21-013) and resources that could help.

Date/Time: Friday, September 22, 2023, 11 am - 12 pm PT (2 pm - 3 pm ET)

More information: https://dknet.org/about/blog/2652

Sep. 25, 2023

Abstract and Registration Deadline: 2023 NMRI West Region Workshop

More than 700 researchers have participated in NMRI workshops in the past decade, and approximately 100+ are active members. The success of the NMRI, a network that is “owned” by its members and supported by the NIDDK, begins with the dedication of senior investigators who mentor and serve as role models for junior investigators. The participation of active members and the recruitment of new members is a primary reason for the Network’s success in the past and the reason for confidence that it will continue to grow in the future. Workshop dates: October 24-25, 2023. More information: https://www.niddk.nih.gov/news/meetings-workshops/2023/nmri-west-region-workshop-2023

Location: Las Vegas, NV, USA

Sep. 26-27, 2023

3rd Annual PKD RRC Annual Symposium (Virtual)

Meeting Objectives

Identify state-of-the-art techniques that could be applied to advance our understanding of PKD biology.
Discuss challenges and gaps in PKD research that, if addressed, could move the field forward.
Promote broad awareness of advances in PKD research and highlight existing PKD research resources.
Foster interaction among members of the scientific community, including PKD researchers, early-stage investigators, and researchers who are new to the PKD field.
Obtain feedback from the research community, with respect to what tools and resources are necessary to advance PKD research.

Abstract submission deadline: September 6, 2023
Meeting dates: September 26-27, 2023.
More information: https://www.scgcorp.com/PKDRRC2023/Default

Sep. 28-29, 2023

NIDDK Workshop: Microphysiological Systems (MPS) for Studying T2D, Obesity, and Their Complications

Microphysiological systems (MPS) are in vitro systems that aim to recapitulate higher orders of cell/tissue organization than conventional two-dimensional static cultures and enable disease modeling and drug discovery studies. Advances in biomaterials, microfluidics, and tissue engineering allow for greater control of three-dimensional cell cultures containing multiple cell types and constituting more physiological tissue organization. Meeting Objectives

Gauge the current status of using MPS for research on type 2 diabetes (T2D), obesity, and their complications.
Determine the knowledge gaps that are difficult to study directly in humans and for which traditional in vitro systems and animal models are inadequate.
Identify opportunities to use MPS to increase our understanding of T2D, obesity, and kidney diseases.
Determine realistic goals that could be accomplished in the next 1, 5, and 10 years.

Location: Bethesda, MD, USA

More information: https://www.niddk.nih.gov/news/meetings-workshops/2 023/microphysiological-systems-for-studying-t2d-obesity-and-complications

Funding Opportunities Information and Deadlines in September 2023

Sep. 05, 2023

The Accelerating Medicines Partnership in Common Metabolic Diseases (AMP-CMD) Funding Opportunity Application Due: Cycle 3 Opportunity Pool

This Opportunity Pool, funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), supports research aligned with the AMP-CMD consortium goals of supporting the generation and analysis of genetic association results, epigenomic annotations, and functional studies, and the representation of these results in the Common Metabolic Diseases Knowledge Portal (CMDKP). This application cycle focuses on novel approaches to identify the functional mechanisms underlying associations for cardiometabolic diseases and related traits. Topics of interest include, but are not limited to: (1) Novel computational tools to better identify effector transcripts (2) Improved cell models to analyze gene function (3) Improved cell assays to analyze effector transcript functions in cardiometabolic cell types (adipocytes, myocytes, etc). Application Due Date: September 5, 2023.

More information: https ://kp4cd.org/OP_FOA_2023

Sep. 11, 2023

NIH Funding Opportunity Letter of Intent Due: The Role of Sleep Deficiency in Persons with Type 1 Diabetes: Sleep, Glycemic Control, and Cardiovascular Risk (R01 Clinical Trial Optional)

The purpose of this Notice of Funding Opportunity (NOFO) is to elucidate the contribution of sleep deficiency and circadian disruption to metabolic and cardiovascular pathobiology, disease trajectory, and treatment response in individuals living with Type 1 Diabetes (T1D). The NOFO will support clinically relevant, mechanism focused research on the interface between sleep, circadian rhythms biology, T1D and cardiovascular disease. Multi-disciplinary teams bridging sleep/circadian, diabetes, and cardio vascular research are encouraged. Proposed research should be relevant to the ultimate goal of applying sleep and circadian strategies to improve treatment and outcomes in individuals with T1D, and to mitigate related cardiovascular complications. Observational studies, epidemiology, efficacy trials and basic animal research will not be responsive to this NOFO. Application Due Date: October 11, 2023.

More information: https://dknet.org/about/dknetnews/2654

Sep. 11, 2023

NIH Funding Opportunity Letter of Intent Due: The Role of Sleep Deficiency in Persons with Type 1 Diabetes: Sleep, Glycemic Control, and Cardiovascular Risk (R34 Clinical Trial Optional)

This Notice of Funding Opportunity (NOFO) will support preliminary studies aimed at obtaining information necessary to guide the design of a full randomized control trial to test whether sleep and circadian targeted interventions improve the clinical course and treatment outcomes in individuals with Type 1 Diabetes (T1D). Applications should focus on pilot studies to inform practical and potentially sustainable strategies to improve processes of care and cardiometabolic health outcomes in individuals with T1D. The scope of research for this NOFO includes a range of feasibility metrics (e.g., optimizing recruitment, retention, randomization); intervention logistics (e.g., determine independent variable(s), dose-response, duration); study design/statistical considerations (e.g., determination of effect size, sample size, and statistical power; inclusion/exclusion criteria, control variables); adherence outcomes (measures of patient acceptance of, satisfaction with, and adherence to treatment); assessment of intermediate markers of the intervention (e.g. glycemic control, vascular dysfunction, inflammation, and/or neuroendocrine and metabolic function)\; and selection of primary and/or secondary outcome(s) measures. Ultimately, results from these pilot studies will be used to develop a well-powered\, evidence-based definitive clinical trial that could improve clinical care and cardiometabolic outcomes in individuals with T1D and to inform guidelines for this patient population. Transdisciplinary investigative teams including relevant expertise in sleep/circadian, T1D and cardiovascular research, as well as needed expertise in clinical trial design, biostatistics and other appropriate areas are encouraged. Studies should include active participation of children, adolescents, and/or adults with T1D. This program is not intended to develop or validate new treatments of devices for sleep and/or circadian deficiency. Animal studies will not be considered responsive to this initiative. Application Due Date: October 11, 2023. More information: https://dknet.org/about/dknetnews/2655

Sep. 13, 2023

Diabetes Research Virtual Seminar Series: RNA Splicing: A novel regulatory layer of islet function

Presenter: Lori Sussel, PhD. Professor of Pediatrics, Research Director, Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Center

More information: https://diabetes-virtual-seminar.org/

Sep. 19, 2023

NIH Funding Opportunity Letter of Intent Due: Identification and Characterization of Bioactive Microbial Metabolites for Advancing Research on Microbe-Diet-Host Interactions (R01 Clinical Trial Not Allowed)

The purpose of the Funding Opportunity Announcement is to invite applications to identify and characterize microbial metabolites that will establish causal associations between microbial metabolism and host health and disease. Data acquired through this initiative will be used to create a knowledgebase of microbial metabolites and associated functions that will be provided to the research community. Development of the database and knowledge portal for these awards will be supported under a separate initiative: RFA-DK-21-014, Identification and Characterization of Bioactive Microbial Metabolites for Advancing Research on Microbe-Diet-Host Interactions Knowledgebase Management Center (Clinical Trial Not Allowed).
Letter of Intent Deadline: September 20, 2021; May 20, 2022; September 20, 2022; May 19, 2023 and September 19, 2023
Application Deadline: October 20, 2021; June 22, 2022; October 20, 2022; June 22, 2023; October 19, 2023
More Information: https://grants.nih.gov/grants/guide/pa-files/par-21-253.html

Sep. 25, 2023

NIDDK Funding Opportunity Letter of Intent Due: Post-baccalaureate Research Education Program in Diabetes, Endocrinology and Metabolic Disease s (R25 – Independent Clinical Trial not Allowed)

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research. Letter of Intent: September 25, 2023. Application Due Date: October 25, 2023.

More information: https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-22-037.html

Sep. 26, 2023

NIDDK Funding Opportunity Letter of Intent Due: Collaborative Research Using Biosamples from Type 1 Diabetes Clinical Studies (R01 - Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) invites applications for studies of type 1 diabetes etiology and pathogenesis using data and samples from clinical trials and studies. This opportunity is intended to fund investigative teams collaborating to answer important questions about disease mechanisms leading to improved prevention of type 1 diabetes.
Letter of Intent Deadline: January 28, 2022 ; September 26, 2023Application Deadline: February 28, 2023 ; October 26, 2023
More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-22-021.html

Sep. 26, 2023

NIDDK Funding Opportunity Letter of Intent Due: Clinical, Behavior al, and Physiological Studies of Open- and Closed-loop Platforms: Toward Personalized, Fully Automated, Accessible Systems (R01 Clinical Trial Required)

The purpose of this funding opportunity announcement (FOA) is to promote clinical research using current and emerging technologies to address barriers that limit progress toward physiological pancreatic hormone replacement open- and closed-loop systems. It will support research to: 1) test and improve the safety, reliability, and clinical efficacy of these technologies; 2) address behavioral/psychosocial factors that play a role in the usability and acceptance of these systems and validation of measures that may be used as outcomes for the demonstration of efficacy and benefit; 3) test these technologies in subpopulations of patients not usually included in clinical trials who may benefit the most from their use; 4) test these technologies in individuals who are underserved or in low income and/or racial and ethnic minority groups, and better understand disparities in the use and adoption of these systems; and 5) use the technologies as tools to advance understanding of glucose regulation and its pathophysiology in patients with type 1 diabetes (T1D) including counter-regulation and impaired awareness of hypoglycemia. Research goals include improved metabolic control with decreased glycemic excursions, prevention of acute and chronic complications, and improved quality of life in patients with diabetes and their caregivers. Only human studies will be considered responsive to this FOA, applications involving animal or in vitro studies are not responsive to this FOA.
Letter of Intent Deadline(s): January 28, 2023; September 26, 2023
Application Deadline(s): February 28, 2023; October 26, 2023
More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-22-020.html

Sep. 26, 2023

NIDDK Funding Opportunity Letter of Intent Due: Evaluating Neurocognitive Complications of Pediatric Type 1 Diabetes (T1D) and Potential Risk and Protective Factors – Clinical Centers (U01 Clinical Trial Not Allowed)

The purpose of this Notice of Funding Opportunity (NOFO) is to establish a clinical consortium to better understand the neurocognitive impact of new onset type 1 diabetes (T1D) in pre-pubertal children. Clinical Centers (CCs) will establish a diverse cohort of pre-pubertal children newly diagnosed with T1D and will evaluate disease-related perturbations in neurocognitive function, as well as identify potential clinical, developmental, and/or environmental factors associated with neurocognitive function in T1D. A separate NOFO (RFA-DK-23-009) will establish a Biostatistics Research Center (BRC) to oversee the development and coordination of a core protocol to be adopted by each CC awarded under the current NOFO (RFA-DK-23-010).

The PD(s)/PI(s) of the BRC and the PD(s)/PI(s) from each of the CCs selected via RFA-DK-23-010 will form a cooperative research consortium in conjunction with NIDDK to design and implement a uniform protocol across approximately 10 CCs and the BRC. Findings from this observational study are expected to advance our understanding of the impact of T1D on the developing brain and identify risk and protective factors associated with neurocognitive functioning to ultimately inform on effective strategies to decrease adverse neurodevelopmental outcomes and long-term neurocognitive sequelae of T1D. Letter of Intent Due Date: September 26, 2023. Application Due Date: October 26, 2023.

More information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-23-010.html

Sep. 26, 2023

NIDDK Funding Opportunity Application Due: Evaluating Neurocognitive Complications of Pediatric Type 1 Diabetes (T1D) and Potential Risk and Protective Factors – Biostatistics Research Center (U01 Clinical Trial Not Allowed)

This Notice of Funding Opportunity (NOFO) invites applications for a Biostatistics Research Center (BRC) to participate in a clinical consortium to better understand the neurocognitive impact of new onset type 1 diabetes (T1D) in pre-pubertal children. A separate RFA (RFA-DK-23-010) invites Clinical Centers (CCs) to establish a diverse cohort of pre-pubertal children newly diagnosed with T1D and will longitudinally evaluate disease-related perturbations in neurocognitive function, as well as identify potential clinical, developmental, and/or environmental factors associated with neurocognitive function in T1D.

The PD(s)/PI(s) of the BRC and the PDs/PIs from each of the CCs selected via RFA-DK-23-010 will form a cooperative research consortium in conjunction with NIDDK to design and implement a uniform protocol across approximately 10 CCs and the BRC. Findings from this observational study are expected to advance our understanding of the impact of T1D on the developing brain and identify risk and protective factors associated with neurocognitive functioning to ultimately inform on effective strategies to decrease adverse neurodevelopmental outcomes and long-term neurocognitive sequelae of T1D. Letter of Intent Due Date: September 26, 2023. Application Due Date: October 26, 2023.

More information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-23-009.html

Sep. 26, 2023

NIDDK Funding Opportunity Letter of Intent Due: Integration of Novel Measures for Improved Classification of Type 2 Diabetes – Biostatistics Research Center (U01 Clinical Trial Not Allowed)

This NOFO invites applications for a Biostatistics Research Center to participate in a consortium aimed at improving understanding of heterogeneity of type 2 diabetes (T2D). A separate NOFO (RFA-DK-23-019) will bring together investigative teams for integration of multiple data types, including markers of organ or tissue function, into analysis approaches for stratifying individuals T2D and developing more precise definitions of disease. The ultimate goal of this effort will be to 1) develop a broadly applicable framework for identifying subtypes of T2D; and 2) increase understanding of the physiologic drivers of T2D subtypes to guide development of more effective precision interventions. Letter of Intent Due Date: September 26, 2023. Application Due Date: October 26, 2023.
More information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-23-020.html

Sep. 26, 2023

NIDDK Funding Opportunity Letter of Intent Due: Integration of Novel Measures for Improved Classification of Type 2 Diabetes (U01, Clinical T rials Not Allowed)

The purpose of this NOFO is to create a consortium to bring together investigative teams for integration of multiple data types, including markers of organ or tissue function, into analysis approaches for stratifying individuals with type 2 diabetes (T2D) and developing more precise definitions of disease. The ultimate goal of this effort will be to 1) develop a broadly applicable framework for identifying subtypes of T2D; and 2) increase understanding of the physiologic drivers of T2D subtypes to guide development of more effective precision interventions. Letter of Intent Due Date: September 26, 2023. Application Due Date: October 26, 2023.
More information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-23-019.html

Sep. 28, 2023

NIDDK Funding Opportunity Application Due: NIDDK Catalyst Award (DP1 Clinical Trial Not Allowed)

The NIDDK Catalyst Award is designed to complement NIDDK's traditional, investigator-initiated grant programs by supporting individual scientists who propose pioneering and transformational studies in topic areas of interest to NIDDK's Division of Diabetes, Endocrinology and Metabolic Diseases, and to NIDDK's Division of Digestive Diseases and Nutrition. Applications should be focused on major scientific challenges and have the potential to produce an unusually high impact on diseases and conditions that are central to the mission of these two divisions within NIDDK. To be considered responsive to this initiative, the proposed research should reflect new and novel scientific directions that are distinct from concepts and approaches being pursued in the investigator’s research program or elsewhere. Letter of Intent Due Date: August 28, 2023.

More information:

https://g rants.nih.gov/grants/guide/rfa-files/rfa-dk-23-014.html